NXY-059 (BioDeep_00000706872)
代谢物信息卡片
Disufenton sodium
化学式: C11H13NNa2O7S2 (380.9928828)
中文名称: 地舒芬通钠
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)(C)[N+](=CC1=C(C=C(C=C1)S(=O)(=O)[O-])S(=O)(=O)[O-])[O-].[Na+].[Na+]
InChI: /q
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D020011 - Protective Agents > D000975 - Antioxidants
C26170 - Protective Agent > C275 - Antioxidant
D002317 - Cardiovascular Agents
同义名列表
2 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mourad Chioua, Emma Martínez-Alonso, Rafael Gonzalo-Gobernado, Maria I Ayuso, Alejandro Escobar-Peso, Lourdes Infantes, Dimitra Hadjipavlou-Litina, Juan J Montoya, Joan Montaner, Alberto Alcázar, José Marco-Contelles. New Quinolylnitrones for Stroke Therapy: Antioxidant and Neuroprotective ( Z)- N- tert-Butyl-1-(2-chloro-6-methoxyquinolin-3-yl)methanimine Oxide as a New Lead-Compound for Ischemic Stroke Treatment.
Journal of medicinal chemistry.
2019 02; 62(4):2184-2201. doi:
10.1021/acs.jmedchem.8b01987. [PMID: 30715875] - Brad A Sutherland, Jens Minnerup, Joyce S Balami, Francesco Arba, Alastair M Buchan, Christoph Kleinschnitz. Neuroprotection for ischaemic stroke: translation from the bench to the bedside.
International journal of stroke : official journal of the International Stroke Society.
2012 Jul; 7(5):407-18. doi:
10.1111/j.1747-4949.2012.00770.x. [PMID: 22394615] - Yi-Fang Cheng, Ji Jiang, Pei Hu, Ingalill Reinholdsson, Wenyu Guo, Nils Asenblad, Dag Nilsson. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.
Clinical therapeutics.
2008 Dec; 30(12):2342-53. doi:
10.1016/j.clinthera.2008.12.013. [PMID: 19167593] - N J Mutch, N R Moore, C Mattsson, H Jonasson, A R Green, N A Booth. The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro.
British journal of pharmacology.
2008 Jan; 153(1):124-31. doi:
10.1038/sj.bjp.0707543. [PMID: 17982476] - Mitsuo Watabe, Yi-Fang Cheng, Dag Nilsson, Yohji Itoh, Yuji Kumagai. A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects.
Current medical research and opinion.
2007 Aug; 23(8):1849-57. doi:
10.1185/030079907x210679. [PMID: 17605894] - Patrick D Lyden, Ashfaq Shuaib, Kennedy R Lees, Antoni Davalos, Stephen M Davis, Hans-Christoph Diener, James C Grotta, Tim J Ashwood, Hans-Goren Hardemark, Hannah H Svensson, Larry Rodichok, Warren W Wasiewski, Gabrielle Ahlberg. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial.
Stroke.
2007 Aug; 38(8):2262-9. doi:
10.1161/strokeaha.106.472746. [PMID: 17569876] - Yi-Fang Cheng, Stig Strid, Olof Borgå, Dag Nilsson, Johan Wemer. Active renal secretion of NXY-059, a novel neuroprotectant, is mediated via an organic acid transporter.
Journal of clinical pharmacology.
2007 Jul; 47(7):909-14. doi:
10.1177/0091270007301803. [PMID: 17585119] - Gunilla Huledal, Dag Nilsson, Matts Kågedal, Ingalill Reinholdsson, Yi-Fang Cheng, Hanna Svensson, Olof Borgå, Mischa van Hout. Effect of NXY-059, a novel neuroprotectant, on the pharmacokinetics of a single dose of digoxin in healthy subjects.
Current medical research and opinion.
2007 Jul; 23(7):1531-9. doi:
10.1185/030079907x199646. [PMID: 17559748] - Dag Nilsson, Johan Wemer, Yi-Fang Cheng, Ingalill Reinholdsson, Gunnar Englund, Nils Egberg, Sam Schulman. NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study.
Journal of clinical pharmacology.
2007 Feb; 47(2):264-72. doi:
10.1177/0091270006293752. [PMID: 17244778] - Stig Strid, Dag Nilsson, Olof Borgå, Johan Wemer, Anders Grahnén. NXY-059 does not significantly interact with furosemide in healthy volunteers.
Journal of clinical pharmacology.
2006 Dec; 46(12):1417-25. doi:
10.1177/0091270006293372. [PMID: 17101741] - Victor L Serebruany. Hypokalemia, cardiac failure, and reporting NXY-059 safety for acute stroke.
Journal of cardiovascular pharmacology and therapeutics.
2006 Dec; 11(4):229-31. doi:
10.1177/1074248406297311. [PMID: 17220468] - Johan Wemer, Yi-Fang Cheng, Dag Nilsson, Ingalill Reinholdsson, Bo Fransson, Kerstin Lanbeck Vallén, Lars Nyman, Catarina Eriksson, Staffan Björck, Sam Schulman. Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects.
Current medical research and opinion.
2006 Sep; 22(9):1813-23. doi:
10.1185/030079906x121075. [PMID: 16968585] - A Richard Green, Kerstin Lanbeck-Vallén, Tim Ashwood, Stefan Lundquist, Eva Lindström Böö, Hallgrimur Jonasson, Mark Campbell. Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia.
Brain research.
2006 Feb; 1072(1):224-6. doi:
10.1016/j.brainres.2005.12.035. [PMID: 16448628] - José M Ferro, Antoni Dávalos. Other neuroprotective therapies on trial in acute stroke.
Cerebrovascular diseases (Basel, Switzerland).
2006; 21 Suppl 2(?):127-30. doi:
10.1159/000091712. [PMID: 16651823] - György T Balogh, Krisztina Vukics, Arpád Könczöl, Agnes Kis-Varga, Anikó Gere, János Fischer. Nitrone derivatives of trolox as neuroprotective agents.
Bioorganic & medicinal chemistry letters.
2005 Jun; 15(12):3012-5. doi:
10.1016/j.bmcl.2005.04.043. [PMID: 15896960] - A Richard Green, Tim Ashwood. Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
Current drug targets. CNS and neurological disorders.
2005 Apr; 4(2):109-18. doi:
10.2174/1568007053544156. [PMID: 15857295] - Siv Jönsson, Yi-Fang Cheng, Charlotte Edenius, Kennedy R Lees, Tomas Odergren, Mats O Karlsson. Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.
Clinical pharmacokinetics.
2005; 44(8):863-78. doi:
10.2165/00003088-200544080-00007. [PMID: 16029070] - Kirk R Maples, A Richard Green, Robert A Floyd. Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke.
CNS drugs.
2004; 18(15):1071-84. doi:
10.2165/00023210-200418150-00003. [PMID: 15581379] - David M Jackson, Ivan A Sammut. Oxygen free radical traps for the treatment of ischemia-associated organ injury.
Current opinion in investigational drugs (London, England : 2000).
2004 Jan; 5(1):50-4. doi:
". [PMID: 14983973] - A Richard Green, Tim Ashwood, Tomas Odergren, David M Jackson. Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059.
Pharmacology & therapeutics.
2003 Dec; 100(3):195-214. doi:
10.1016/j.pharmthera.2003.07.003. [PMID: 14652110] - Jonathan W B Marshall, Rosalyn M Cummings, Laura J Bowes, Rosalind M Ridley, A Richard Green. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion.
Stroke.
2003 Sep; 34(9):2228-33. doi:
10.1161/01.str.0000087790.79851.a8. [PMID: 12920263] - K R Lees, D Barer, G A Ford, W Hacke, V Kostulas, A K Sharma, T Odergren. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke.
Stroke.
2003 Feb; 34(2):482-7. doi:
10.1161/01.str.0000053032.14223.81. [PMID: 12574564] - Stig Strid, Olof Borgå, Charlotte Edenius, Karl-Gustav Jostell, Tomas Odergren, Angelika Weil. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
European journal of clinical pharmacology.
2002 Sep; 58(6):409-15. doi:
10.1007/s00228-002-0478-x. [PMID: 12242600] - S G Sydserff, A R Borelli, A R Green, A J Cross. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window.
British journal of pharmacology.
2002 Jan; 135(1):103-12. doi:
10.1038/sj.bjp.0704449. [PMID: 11786485] - Z Zhao, M Cheng, K R Maples, J Y Ma, A M Buchan. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat.
Brain research.
2001 Aug; 909(1-2):46-50. doi:
10.1016/s0006-8993(01)02618-x. [PMID: 11478919] - K R Lees, A K Sharma, D Barer, G A Ford, V Kostulas, Y F Cheng, T Odergren. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke.
Stroke.
2001 Mar; 32(3):675-80. doi:
10.1161/01.str.32.3.675. [PMID: 11239186]